Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939065 · ClinicalTrials.gov registry record · NA
Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03939065 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 1 participants.
The verdict
NCT03939065, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This research proposes a pilot study using the combination of continuous glucose monitor (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic fibrosis related diabetes (CFRD) management in the inpatient setting, with the aim of improving glycemic control.
Interventions
- DEVICE Sensor Augmented Pump Therapy
- DEVICE Standard of Care with CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03939065
The ClinicalTrials.gov registry entry for NCT03939065 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sensor Augmented Pump Therapy is the first listed.
NCT03939065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03939065 about?
NCT03939065 is a clinical study titled "Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management". This research proposes a pilot study using the combination of continuous glucose monitor (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic fibrosis related diabetes (CFRD) management in the inpatient setting, with the aim of improving glycemic control.
What is the current status of trial NCT03939065?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2020-06-12. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03939065?
The interventions under investigation include: Sensor Augmented Pump Therapy (DEVICE), Standard of Care with CGM (DEVICE).
Who is sponsoring clinical trial NCT03939065?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.